The Innovation Reduction Act with Allan Shaw
Business Of Biotech
00:00
The Cost Paradigm and the Intent to Reduce Healthcare Costs
Some conditions and people will be experiencing lower costs. Many will also potentially result in higher costs to restricted access if rebates are misplaced by price setting. If you don't have medicines that come to market, it's also going to cost patients more money because the system will cost more money. The timing for market exclusivity goes off on the very first product approval.
Transcript
Play full episode
